RegeneRx Biopharmaceuticals, Inc.
http://www.regenerx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From RegeneRx Biopharmaceuticals, Inc.
Biocon Expects US Adalimumab Market To Consolidate, Liraglutide Plans On Course
Biocon maintains it doesn’t expect the US to remain an eight to 10 player market for adalimumab biosimilars for long and also outlines expectations for its GLP-1 portfolio, led by liraglutide, seen as a major growth driver in the coming years.
Samsung Bioepis Hit By Amgen Denosumab Lawsuit
Amgen has asserted 34 patents for alleged infringement against Samsung Bioepis, which is the highest number out of the three lawsuits filed by the originator against a denosumab biosimilar maker.
Biocon Expects US b(Humira) Market To Consolidate, Liraglutide Plans On Course
Biocon maintains it doesn’t expect the US to remain an eight to 10 player market for adalimumab biosimilars for long and also outlines expectations for its GLP-1 portfolio, led by liraglutide, seen as a major growth driver in the coming years.
Madrigal Likes Rezdiffra’s Long-Term Positioning In NASH
Despite a share price decline, Madrigal CEO Bill Sibold tells Scrip he is confident that Rezdiffra is off to a strong launch, backed by promising metrics and a solid strategy.
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Biomaterials
-
Biotechnology
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice